Karin Schölin Bywall

Karin Schölin Bywall

Karin Schölin Bywall

MSc Public Health
PhD Student

Karin Schölin Bywall is a PhD student in the IMI-funded PREFER project. The project is aiming to investigate methodologies to elicit informed patient preferences regarding the benefits and risks of drugs, from development through the entire cycle, to inform the decision-making process by regulators and HTA bodies.

Karin Schölin Bywall has a master of science in public health from Mälardalen University where she also teached in public health.

E-mail: karin.bywall@crb.uu.se
Phone: +46 18 471 62 49
 

Publications

  • Falahee, Marie; Simons, Gwenda; DiSantostefano, Rachael; Valor Méndez, Larissa et al.

    Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project

    Part of BMJ Open, 2021.

    Open access
  • Schölin Bywall, Karin

    Getting a Say: Bringing patients’ views on benefit-risk into medical approvals

    Open access
  • Schölin Bywall, Karin; Veldwijk, Jorien; Hansson, Mats G.; Baecklund, Eva et al.

    Does being exposed to an educational tool influence patient preferences? The influence of an educational tool on patient preferences assessed by a discrete choice experiment.

    Part of Patient Education and Counseling, 2021.

  • Whichello, Chiara; Schölin Bywall, Karin; Mauer, Jonathan; Watt, Stephen et al.

    An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?

    Part of Health Policy, p. 1325-1332, 2020.

    Open access
  • Schölin Bywall, Karin; Kihlbom, Ulrik; Hansson, Mats; Falahee, Marie et al.

    Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients

    Part of Arthritis Research & Therapy, 2020.

    Open access
  • Schölin Bywall, Karin; Veldwijk, Jorien; Hansson, Mats G.; Kihlbom, Ulrik

    Patient Perspectives on the Value of Patient Preference Information in Regulatory Decision Making: A Qualitative Study in Swedish Patients with Rheumatoid Arthritis

    Part of Patient, p. 297-305, 2019.

    Open access
  • van Overbeeke, Eline; Janssens, Rosanne; Whichello, Chiara; Schölin Bywall, Karin et al.

    Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study

    Part of Frontiers in Pharmacology, 2019.

    Open access
  • Whichello, Chiara; van Overbeeke, Eline; Janssens, Rosanne; Schölin Bywall, Karin et al.

    Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US

    Part of Frontiers in Pharmacology, 2019.

    Open access
  • Janssens, Rosanne; Russo, Selena; van Overbeeke, Eline; Whichello, Chiara et al.

    Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA

    Part of Patient, p. 513-526, 2019.

    Open access
  • Whichello, Chiara; Schölin Bywall, Karin; Mauer, Jonathan; Watt, Stephen J. et al.

    Mapping benefit-risk decision-making processes and identifying decision points with the potential to include patient preference information throughout the medical product lifecycle

    Part of Pharmacoepidemiology and Drug Safety, p. 206-206, 2018.

    Open access

Methodology, rheumatoid arthritis and patient involvement

Drugs should benefit patients. By extension, they should have a say in designing research meant to find out what they think about drugs. Here, Karin Schölin Bywall shares her thoughts about involving patients in research and working together with stakeholders.

Read interview

Karin Schölin Bywall
Last modified: 2021-03-04